Users should refer to the original published version of the material for the full abstract. No warranty is given about the accuracy of the copy. However, users may print, download, or email articles for individual use. 12 The low-dose regimen would cost half as much. Treatment with the high dose would cost 49 500 for the drug alone. it is currently available at only ten institutions. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. Idarucizumab (Praxbind) was approved in 2015 for reversal of the anticoagulant effect of the direct thrombin inhibitor. Copyright of Clinical & Applied Thrombosis/Hemostasis is the property of Sage Publications Inc.However, a higher prevalence of ICH bleeds was noted in the andexanet alfa group. Conclusions: Anticoagulant reversal therapy with idarucizumab was associated with significantly lower adjusted mean total hospital and ICU costs compared with andexanet alfa. Results: Idarucizumab patients were older than andexanet alfa patients (median age 81 vs 77 years p < 0.001), and less likely to experience intracranial hemorrhage (ICH) (37.1%vs 73.8% p = 0.001). Inverse of treatment probability weighting (IPTW) method was used to balance patient and clinical characteristics between treatment cohorts. Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included patients aged ≥18 years on direct oral anticoagulants (DOACs) who experienced life-threatening bleeds, discharged from the hospital during –, and received idarucizumab or andexanet alfa.
0 Comments
Leave a Reply. |